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As more research studies incorporate next-generation sequencing (including whole-genome or whole-exome sequencing), investigators
and institutional review boards face difficult questions regarding which genomic results to return to research participants and how. An
American College of Medical Genetics and Genomics 2013 policy paper suggesting that pathogenic mutations in 56 specified genes
should be returned in the clinical setting has raised the question of whether comparable recommendations should be considered in
research settings. The Clinical Sequencing Exploratory Research (CSER) Consortium and the Electronic Medical Records and Genomics
(eMERGE) Network are multisite research programs that aim to develop practical strategies for addressing questions concerning the
return of results in genomic research. CSER and eMERGE committees have identified areas of consensus regarding the return of genomic
results to research participants. In most circumstances, if results meet an actionability threshold for return and the research participant
has consented to return, genomic results, along with referral for appropriate clinical follow-up, should be offered to participants.
However, participants have a right to decline the receipt of genomic results, even when doing so might be viewed as a threat to the
participants’ health. Research investigators should be prepared to return research results and incidental findings discovered in the course
of their research and meeting an actionability threshold, but they have no ethical obligation to actively search for such results. These
positions are consistent with the recognition that clinical research is distinct from medical care in both its aims and its guiding moral
principles.Introduction
The growth of next-generation sequencing and the vast
amounts of data that sequencing potentially provides
for interpretation require the review of policies for return-
ing results to participants. As the technology and the
type of results available continue to evolve, this area re-
quires ongoing scrutiny. An American College of Medical
Genetics and Genomics (ACMG) policy paper published
in 20131 and associated clarification2 have addressed the
return of incidental findings to patients undergoing clinical
genomic sequencing tests and have directed attention to
whether recommendations of this kind should be consid-
ered by the research community. Members of the Return
of Results (ROR) committees of the Clinical Sequencing
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area and worked to identify consensus recommendations.
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important health implications such as premature death or
substantial morbidity or has significant reproductive im-
plications; and proven therapeutic or preventive interven-
tions are available.’’ This concept of clinical utility is often
summarized as ‘‘actionable’’ genetic results. The issue of re-
turn of genomic results was reviewed in 2010 by a second
working group and reported by Fabsitz et al.5 This group
offered further recommendations and emphasized that
consent from a research participant is a necessary precon-
dition for returning results. The group struggled with
whether research results offered for return must be gener-
ated by a laboratory that complies with the Clinical
Laboratory Improvement Amendment (CLIA) regulations
of 19886 in order to be returned, and the group recom-
mended that this question be further evaluated. A 2008
NIH-supported research group offered consensus recom-
mendations reinforcing the need for consent from a
research participant in order for incidental findings to be
returned and similarly concluded that ‘‘more work’’ was
needed for resolving the CLIA issue.7 This group’s recom-
mendations emphasized the difference between research
and clinical care and noted that researchers ‘‘generally
have no obligation to.affirmatively search for’’ incidental
findings. A related NIH-supported research group offered
recommendations in 2012 for genomic research involving
biobanks, again emphasizing the importance of consent
for the return of individual research results and incidental
findings and calling for ‘‘working with the CMS [Centers
for Medicare & Medicaid Services], the agency that admin-
isters CLIA’’ to resolve the question of how to handle re-
sults generated in a lab that is not CLIA certified.8 Finally,
the Presidential Commission for the Study of Bioethical
Issues has addressed the return of incidental findings in
whole-genome sequencing9 and then more broadly in
research.10 In both reports, they have stressed the impor-
tance of seeking the research participant’s consent for the
return of incidental findings. The latter report concludes
that investigators have no duty to affirmatively hunt for
such findings and notes the ongoing debate about CLIA’s
application to the return of findings from laboratories
without CLIA certification.
Considerable research has addressed research partici-
pants’ desires regarding the return of genetic and genomic
research results. Data demonstrate that a majority of
research participants express interest in receiving clinically
significant individual study results.11,12 Participants
consider the potential for treatment and prevention,
understanding of a disease, and respect for research
participants’ right to receive results as compelling reasons
for investigators to share research results with partici-
pants.13–15
As the research community has been grappling with
issues around the return of research results and incidental
findings, the ACMG published a policy paper1 addressing
the return of incidental findings in clinical settings. The
recommendations and ensuing discussion have led the
research community to consider the applicability of theseThe Amor similar recommendations in research contexts. The
ACMG recommendations urge that laboratories evaluate
and return known pathogenic and expected pathogenic
variants in 56 genes when those data are available through
clinical next-generation sequencing tests, including
whole-genome or whole-exome sequencing performed
for diagnostic or treatment purposes for any indication,
including when germline testing is done as part of a
tumor-normal pair in oncology. The ACMG clinical recom-
mendations have generated much controversy.16–21 How-
ever, little of the controversy revolves around the actual
list of minimum genes suggested, although larger lists
have been offered, including those from members of the
CSER Consortium.22 Rather, the controversy has been
focused on two issues. One issue is the recommendation
of mandatory analysis and return of results, even if the pa-
tient does not desire such information; it has been argued
that this might be inconsistent with established norms of
respect for patient autonomy20,23 and might pose liability
risks that need to be managed carefully.21 Notably, the
ACMG has recently abandoned the mandatory position
in favor of a patient opt-out of the analysis and return of
incidental findings.24 The second major area of contro-
versy centers on the return of pathogenic variants for
adult-onset conditions to children.25 Nonetheless, the
specific question of whether these or comparable recom-
mendations should be extended to research genomic tests
has been frequently raised. This debate underscores the
need for an updated consideration of which genomic
content should be evaluated and which results should be
returned in the research setting.Material and Methods
Process
A joint meeting of the CSER Consortium and eMERGE Network
in October 2013 included the ROR committees of both groups.
This meeting identified the return of genomic results to research
participants as an area of joint concern. Those attending agreed
on some basic principles to inform the return of research results,
including incidental findings. A written proposal to produce a
paper summarizing these basic principles was shared with both
consortia, and all members were invited to join the process.
Whereas the CSER Consortium Actionability (Act)-ROR group
encompasses a large bioethics presence, the eMERGE bioethics
group is spread between the ROR and CERC working groups;
thus, the latter group was formally invited to join the process.
A small writing team wrote a first draft based on the October
discussion and then shared it with co-authors for primary
input. That product was then reviewed by the working groups,
whose feedback was incorporated in an iterative process of
revision.
Guiding Principles
Principle 1: Research, even in a clinical setting, differs from
clinical care in both its goals and its procedures; as a result,
the minimal and maximal information returned in a research
setting might differ from standards of clinical practice.erican Journal of Human Genetics 94, 818–826, June 5, 2014 819
820Principle 2: Resources for research should be primarily directed
at scientific discovery; thus, researchers do not have a duty to
look for actionable genomic findings beyond those uncovered
in the normal process of their investigations.
Principle 3: Research assessing the outcomes of a wide range of
potential practices for returning genomic results is required for
the ultimate formulation of best practices in both the research
and the clinical settings.
Principle 4: Analytically and clinically valid information that is
of an important and actionable medical nature and that is
identified as part of the research process should be offered to
a research participant.
Principle 5: Participants should have the right to refuse any re-
sults that are offered. Potential research participants or parents
of minors eligible for research studies should be provided
proper informed consent that respects autonomy, including
the right to refuse participation in research. If the return of
results is essential to the purpose of the study, potential partic-
ipants should be adequately informed at the time of recruit-
ment so they are able to decline participation if they do not
want to receive results and should be reminded of their right
to withdraw prior to any return of results.Results and Discussion
Areas of Consensus
Principle 1
‘‘Research, even in a clinical setting, differs from clinical
care in both its goals and its procedures; as a result, the
minimal and maximal information returned in a research
setting might differ from standards of clinical practice.’’
This principle acknowledges that standards for return prac-
tices in the research setting should not be driven purely by
clinical standards. The distinction between research, an
activity focused on the acquisition of generalizable knowl-
edge, and clinical care, an activity focused on the treat-
ment and decision making for the patient, is important
in determining an appropriate practice for the return of
genomic research results.21,26 Despite the frequent attesta-
tions that genome-scale sequencing is ‘‘blurring the lines
between research and clinical practice,’’ these endeavors
have distinct goals and characteristics. The relationship
between the physician and the patient differs from the
relationship between the researcher and the research
participant and incorporates the legal responsibilities of
patient care on the part of the clinician. That said, re-
searchers should acknowledge certain important ethical
obligations toward participants, including respect for per-
sons, a duty to avoid harm, and a duty to rescue27 in
defined circumstances.
Principle 2
‘‘Resources for research should be primarily directed at
scientific discovery; thus, researchers do not have a duty
to look for actionable genomic findings beyond those
uncovered in the normal process of their investigations.’’
This principle acknowledges that the return of genomic
research results represents an investment of limited
research resources and that returnable results are foundThe American Journal of Human Genetics 94, 818–826, June 5, 2in a small proportion of participants.28 We therefore do
not endorse the requirement to search for ‘‘incidental
findings,’’ such as that proposed in the ACMG 2013
recommendations, in the research context. Although the
ACMG recommends a hunt for incidental findings in a
predetermined list of genes whenever relevant clinical
sequencing is undertaken, the term ‘‘incidental’’ is some-
what of a misnomer and has been propagated by the
common misconception that identifying such results is
unavoidable. Although most routine variant-calling algo-
rithms capture all genetic variants (if present) across the
entire genome, most study designs do not require these
data to be evaluated, and thus the presence or absence of
a meaningful genetic variant is usually unknown to the
investigator unless a purposeful examination of a partic-
ular gene is undertaken. Further, even if these data are
generated and evaluated, confirming that a purported dis-
ease-causing variant is actually pathogenic often requires
extensive review, including evaluation of the primary
literature. Even in a highly automated study reported
by Dorschner et al., which included most of the genes
proposed by the ACMG, among others, this work required
an average of 20 min of review per variant (the majority of
which were nonpathogenic), and some variants required
hours of review and discussion.28 Issues also arise in the
return of such results. Further resources must be utilized
for providing confirmation in a CLIA-compliant lab (if
required) and for returning the result. Additionally, some
investigative teams are not qualified to interpret and/or
return the results. Thus, although it is true that in a large
study some participants might have their health protected
by the search for and the return of genomic ‘‘incidental
findings,’’ such activities require expertise and substantial
investment in resources. Notably, the recent Presidential
Commission for the Study of Bioethical Issues considering
incidental findings has also concluded that researchers do
not have a ‘‘duty to hunt.’’10
It would be exceptional to mandate the use of research
funds to hunt for ‘‘incidental findings,’’ in effect a low-
yield preventive health screening of participants; if this
were recommended, one could think of many interven-
tions that would most likely yield a higher benefit. In addi-
tion, as discussed earlier, research is separate from the
provision of medical care and screening; researchers are
not obligated to develop expertise and expend additional
resources to look for variants to return. Rather, we favor
defining the ‘‘floor’’ for the offer of the return of genomic
results in research studies to include highly actionable
findings that are relevant to the intent of the research
study or that are ‘‘stumbled upon’’ in the course of
research. Relevant costs to a study could be estimated
and included in the budget, and granting agencies should
allow these costs. Any obligation to return results would
not extend beyond the funding period. Similarly, it would
be unreasonable to expect all researchers engaged in
genomic research to provide their research participants
with broad access to genomic results if doing so in a014
responsible way represented an unreasonable burden that
distracted from the intent and purpose of their research
studies.
Principle 3
One of the broad goals of genomic research, and a specific
goal of the CSER Consortium and eMERGE Network, is
to better understand the optimal return of results. In
order to do this, one should explore a variety of methods.
This leads to principle 3, ‘‘research assessing the outcomes
of a wide range of potential practices for returning
genomic results is required for the ultimate formulation
of best practices in both the research and the clinical
settings.’’
We recognize a range of possible results that could be re-
turned in a research setting; we define the minimal ‘‘floor’’
as the return of well-established, important actionable
genetic findings relevant to the intent of the research study
or uncovered in the course of usual research procedures,
and we define the ‘‘ceiling’’ as the entire genome sequence
or some representation of it. Thus, for the return of results
in a research setting, the ‘‘floor’’ would be lower than the
clinical return policy of the ACMG recommendations,
and the ‘‘ceiling’’ of acceptable return (including of the
entire genome) would be higher for at least the near future.
Findings from CSER, eMERGE, and other research studies
investigating a wide range of practices for the return of
genomic results will help inform current and future pol-
icies for both research and clinical return-of-results recom-
mendations in this area.
As genomic medicine becomes more common, we can
anticipate that patients might be given direct access to
the entirety of their genomic information. This warrants
research that delves into optimal procedures for doing
this, including pretest counseling, informed consent,
posttest understanding, avoidance of misinterpretation,
health-care and personal utility, and cost evaluation.
Therefore, researchers might elect to return all genomic in-
formation. Research into these and related questions
might be best designed to return a variety of information
between these extremes. For example, research on the
effects of variants on medication prescribing and compli-
ance might only require the return of pharmacogenomic
data.
Principle 4
Endorsed by Bookman et al.,4 Fabsitz et al.,5 and others, we
recognize that when investigators have a valid research
result that will allow preventive or other steps important
to protect the participant’s health, these data should be
offered to identifiable research participants. This is sup-
ported by the fourth principle that ‘‘analytically and
clinically valid information that is of an important and
actionable medical nature and that is identified as part of
the research process should be offered to a research partic-
ipant.’’ This assumes that the participant has consented to
the return of results in the informed-consent process. The
definition of what is actionable is a matter of judgment.
The gene-disease pairs offered by the ACMG might be aThe Amreasonable starting place for consideration, although there
are clearly other equally actionable, if rarer, examples.28
Further, what is appropriate for return might depend on
context,27 such as the age of the participant. What is
considered returnable should be examined by the investi-
gators and outlined in the consent process. We also sup-
port the Fabsitz et al. position that the investigators’
responsibility to return does not extend beyond the period
of funding, although investigators might elect to return
results beyond that timeframe. We also suggest that sec-
ondary users of data return information to the primary
investigators but are not themselves obligated to return re-
sults to participants. We acknowledge that some studies,
including those of anonymized participants, will not be
able to return results.
There has been controversy over whether adult-onset
findings should be offered for pediatric research partici-
pants. Historically, children have not been offered elective
clinical testing for adult-onset conditions. This preserves
their autonomy to make their own decisions regarding
testing when they are adults. However, we acknowledge
that the case of an incidental finding discovered in
sequencing DNA from a child with no prior warning of
that variant in the family is different from the past clinical
case of the known existence of the genetic finding in one
or more other family members. When a family member
is known to carry a pathogenic variant for a highly pene-
trant adult-onset condition for which there is no change
in childhood management (such as screening tests or
diet), there is little possible benefit to the child or family
from testing for this variant during childhood. This is re-
flected in the traditional medical genetics practice guide-
lines that children not be tested for adult-onset conditions
that are known in their family.29–31 However, when the
variant is unknown in the family and a pediatric genomic
test uncovers it as an incidental finding, return alerts fam-
ily members to be tested for it. The ACMG1 authors, in
concluding that these results should be returned in the
clinical setting, regarded the prevention of potential
harm to the transmitting parent and other familymembers
as a benefit to the child. By contrast, the P3G international
pediatrics platform group recently recommended that
‘‘mutations that predispose the child to develop an adult-
onset disorder, even if accidentally discovered in the
research process, generally should not be returned. This
allows the child to make his or her own decision about
receiving the results as an adult.’’ 32 They also added that
‘‘questions, which should arise rarely, of whether the child
would benefit, on balance, from disclosure because of the
potential benefit to the family from knowing about a
highly penetrant gene they may have that poses serious
risk to health and that is preventable or treatable, should
be assessed on a case-by-case basis.’’
This topic calls for further research and analysis. When
an incidental result found in a pediatric research study is
not returned, current practice makes it unlikely that the
result will be offered to the child in adulthood because,erican Journal of Human Genetics 94, 818–826, June 5, 2014 821
unlike a known familial mutation, its existence is not
likely to be tracked. Further, the frequency or rarity of
incidentally discovered mutations whose known exis-
tence might benefit the family warrants research, given
that 1%–4% of participants might have such variants.28
In the case of a pediatric research participant, we are
able to reach consensus and conclude that during the
consent process, the parents should be offered the
choice of whether to have the adult-onset actionable inci-
dental findings returned along with counseling on the
implications for the child’s best interests and the parents’
health status. One caveat to this approach is that in the
case of trio sequencing, where the parents and child are
all sequenced, adult-onset actionable findings that do
not change management during childhood and are
detected in a parent need not be offered for return to the
child.
Principle 5
This principle states that ‘‘participants should have the
right to refuse any results that are offered. Potential
research participants or parents of minors eligible for
research studies should be provided proper informed con-
sent that respects autonomy, including the right to refuse
participation in research. If the return of results is essential
to the purpose of the study, potential participants should
be adequately informed at the time of recruitment so
they are able to decline participation if they do not want
to receive results and are reminded of their right to with-
draw prior to any return of results.’’
At the time of consenting, participants should be
given the opportunity to refuse the return of genetic
findings, unless the purpose of the study is dependent
on result return, in which case consent to participate
in the study necessarily involves consent to receive
results. In the latter case, participants may decline
enrollment.
Studies suggest that research participants vary in their
desire for genomic results. Many research participants
would like more than highly actionable data, including
data on nonactionable findings.33,34 This is born out in
the market for direct-to-consumer testing, suggesting in-
terest by some for information about minimally actionable
conditions, ancestry information, and carrier status for
recessive diseases. On the other hand, a substantial num-
ber of participants indicate that they want no genomic
information or assign nomonetary value to having this in-
formation.35 Research on these varying levels of return,
ranging from the ‘‘floor’’ to the ‘‘ceiling,’’ will not always
honor participant preferences. It is ethical to not share
genomic information that some participants might want
as long as they have a clear understanding of the limits
when they enroll in the study. The converse might not
always be true, however. It might not be ethical to return
results that participants do not want if they feel compelled
to be in a study for possible medical gain. For example,
patients undergoing research-based tumor sequencing for
possible direction of chemotherapy should be able to822 The American Journal of Human Genetics 94, 818–826, June 5, 2decline the return of incidental findings not related to
their cancer treatment. Participation in research studies
should be as noncoercive and respectful of participant
choice as possible.
The consent process and form should address the possi-
bility that there might be both research results related to
the primary intent of the research and findings that are
incidentally discovered in the course of research, and par-
ticipants should be able to clearly opt in or out of receiving
these types of results either at the time of initial consent or
at a later point in the study when the specific types of re-
sults the participants might receive can be best defined.
Framing the conversation as ‘‘if we find.would you
want’’ avoids the potentially coercive ‘‘we have.do you
want.’’ Ideally, the original consent form would include
the possibility for, or an option of, future contact to offer
results not anticipated at the time of consenting. If, as a
result of the study design, it is not possible to refuse genetic
research findings, this should be clearly outlined and con-
sented to in the informed-consent process. Participant
preferences might play a role in the choice of which
research results should be returned in that all participants
might not choose the same options as those deemed clin-
ically significant. Research is warranted for how to best
educate participants on their options and possibly offer
more choices on types of results for return. Although we
do not anticipate a scenario in which an opt-out of
genomic findings or future contact would be overruled
by the study team, we do envision a role for the local IRB
or data- and safety-monitoring board as to whether the
opt-out might be overruled if unexpected and clinically
urgent circumstances arise.
We suggest that, when feasible, participants be reminded
of their right to refuse genomic results prior to receiving
them. Circumstances that lead participants to change their
minds are another important area for research. We do not
believe written reconsent is required prior to the return of
results.
Parents too should be able to refuse the return of results
and incidental findings when their children participate in
genomic research. This latitude to refuse may be limited,
however, when the results hold high and actionable health
significance for the minor during childhood. This is in
keeping with the broad discretion generally accorded to
parents to make health decisions in their child’s best inter-
ests, except regarding conditions that threaten life or sig-
nificant impairment.36–38
Areas of Controversy
Our group has two remaining areas of controversy in the
return of research results: (1) the role of CLIA compliance
and (2) the optimal methods for return. Each of these
areas would benefit from additional research. In the first
area, Fabsitz et al.5 did not reach consensus on whether
results returned to participants must be CLIA compliant.
We agree that results whose accuracy or sample origin is
in question should not be returned without compelling014
reasons and careful explanation. There is also general
agreement that prospective studies that include a plan
to return genetic results should derive or confirm those
results in CLIA-compliant labs when possible. However,
actionable information might be learned from assays
that cannot be easily confirmed in a CLIA-compliant lab-
oratory. In addition, even if the result can be confirmed,
the existing samples might not have been obtained and
stored through a CLIA-compliant sample-tracking process,
and a new specimen must also be obtained for ensuring
that no sample mix-up occurred. One option is to disclose
the non-CLIA-compliant results as research results with
the caution that no clinical action should be taken
on the basis of those results while providing information
about how to proceed with clinical confirmation in a
process of clinical evaluation and follow-up. This clinical
confirmation might require a genetics professional, given
that primary-care providers might not have the expertise
to order a confirmatory test and perform counseling.
Some have suggested that the return of the non-CLIA
result and subsequent referral to appropriate care for a
CLIA test, if desired, not be allowed under the CLIA regu-
lations; however, the only published legal analysis con-
cludes that this approach is within the CLIA research
exception and therefore does not trigger the need for
CLIA compliance.26,39 This analysis also concludes that
there is a First Amendment right for a willing researcher
to share non-CLIA results with a willing participant,39
although this interpretation has not been tested in court.
Given that research circumstances might make a CLIA-
compliant test impossible, research into whether there
is harm or benefit to sharing non-CLIA results might be
helpful.
The second area of controversy, the method of return,
also requires further research. Results should be communi-
cated effectively and presented in a way that is understood
by the participant and their health-care provider. Research
is under way on how best to integrate genomic findings
into the medical record and which alerts or decision-sup-
port prompts would aid the provider. The clinician is
then responsible for integrating the results into a clinical-
care plan as appropriate in consultation with the patient.
Access to follow-up clinical care should be available.
Optimal methods for communicating genomic results
will vary with context and will ideally maintain a clear
boundary between clinical care and research. Some have
proposed that genetic research results only be returned
by a genetic counselor or other qualified clinical provider.
Others have investigated other methods for return, such
as by the primary-care provider or through computer-aided
or web-based return.40,41These latter models are driven by
the expectation that genomic results will become more
common and that their return will require nongenetics
professionals, given how few clinical geneticists and
genetic counselors are available. Again, research com-
paring methods of results return could help identify best
practices.The AmConsensus Recommendations
1. At a minimum (the ‘‘floor’’), researchers should offer
individual genomic research results that are valid,
medically important, and actionable if discovered
purposefully or by chance during the course of data
analysis. Investigators are not obligated to search
for actionable genomic variants to be returned
beyond those identified in the course of their
research, that is, there is no duty to hunt.eria. Given that there is no definitive ‘‘list’’ of medically
actionable findings with respect to the return of
research results and incidental findings and that
such a list would be context dependent, those
involved in genomics research should give
thought to the types of findings that would repre-
sent the ‘‘floor’’ for return in their study in consul-
tation with local IRBs and funding agencies. The
ACMG list, currently containing 56 genes, is a
reasonable starting point for consideration;1
however, more comprehensive lists have been
offered.22
b. The responsibility to offer disclosure of results and
incidental findings is limited to circumstances in
which there are identifiable participants and to
the period of funding to investigators, although
investigators may elect to offer disclosure after
that term.
2. Participants should have the option to refuse
research genomic test results, both those related to
the study purpose and those that are incidental find-
ings, unless the study aims are related to the return of
these data. Plans for return and the participants’
option to refuse offered results should be addressed
at the time of consent.
a. When studies do not allow participants to opt
out of potentially receiving results, this and the
opportunity to withdraw prior to receiving results
should be clearly addressed in the consent process
and form.
b. The consent process and form should clarify
the circumstances in which a participant might
be contacted in the future and explicitly
ask whether the participant consents to future
contact if new findings are found. Partici-
pants who are contacted regarding such results
should have the right to decline receiving those
results.
c. Participation in research studies should be non-
coercive and respectful of participant choice.
d. Parents of minors participating in genomic
research should generally have the same right
to refuse, unless the return of the results is
of high health significance to the minor in
childhood. Investigators may reasonably offer
the parents of minors participating in pediatric
research the option of accepting or refusing
results for adult-onset conditions along withcan Journal of Human Genetics 94, 818–826, June 5, 2014 823
824counseling on the implications for the child’s
best interests and the parents’ health status. In
the case of trio testing, parents may be offered
only their own adult-onset results and not their
child’s, unless the child has a relevant de novo
mutation.
3. Researchers might be ethically and scientifically
justified in returning all genomic information (the
‘‘ceiling’’) in some format and any level of informa-
tion in between the ‘‘floor’’ of actionable results iden-
tified during the course of research and the ‘‘ceiling’’
of all genomic information.
a. Special care should be taken when the benefits
and harms of returning a particular type of
genomic information are uncertain.
b. Investigators should take steps to assure adequate
analytic and clinical validity for return, including
systems to avoid sample mix-up. Further work is
needed on the role of CLIA compliance in the
return of research results.
c. Research studies intended to examine practices for
the return of genomic information should include
measurements of benefits and harms in the design
of the study.
4. Additional research projects that examine the poten-
tial benefits and harms of receiving genomic results
and evaluate practices for returning genomic infor-
mation are required to inform the increasing use of
genomic sequencing in clinical research.Consortia
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